Are changes in olanzapine-induced liver enzyme levels associated with GSTT1, GSTM1, GSTP1, and OGG1 gene polymorphisms?

1. NIH National Library of Medicine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [displayed 15 February 2024]. Available at https://www.ncbi.nlm.nih.gov/books/NBK547852/ NIH National Library of Medicine LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Bethesda (MD) National Institute of Diabetes and Digestive and Kidney Diseases 2012 [displayed 15 February 2024]. Available at https://www.ncbi.nlm.nih.gov/books/NBK547852/ Search in Google Scholar

2. David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev 2010;6:73–80. PMCID: PMC3160634 DavidS HamiltonJP Drug-induced liver injury US Gastroenterol Hepatol Rev 2010 6 73 80 PMC3160634 Search in Google Scholar

3. Abdel-Moneim SM, Sliem H. Significance of serum alpha-glutathione S-transferase assessment in hepatitis C patients with different alanine aminotransferase patterns. Gastroenterology Res 2011;4:13–9. doi: 10.4021/gr269w Abdel-MoneimSM SliemH Significance of serum alpha-glutathione S-transferase assessment in hepatitis C patients with different alanine aminotransferase patterns Gastroenterology Res 2011 4 13 9 10.4021/gr269w Open DOISearch in Google Scholar

4. Giffen PS, Pick CR, Price MA, Williams A, York MJ. Alpha-glutathione S-transferase in the assessment of hepatotoxicity - its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 2002;30:365–72. doi: 10.1080/01926230252929945 GiffenPS PickCR PriceMA WilliamsA YorkMJ Alpha-glutathione S-transferase in the assessment of hepatotoxicity - its diagnostic utility in comparison with other recognized markers in the Wistar Han rat Toxicol Pathol 2002 30 365 72 10.1080/01926230252929945 Open DOISearch in Google Scholar

5. Maina I, Rule JA, Wians FH, Poirier M, Grant L, Lee WM. α-glutathione S-transferase: a new biomarker for liver injury? J Appl Lab Med 2016;1:119–28. doi: 10.1373/jalm.2016.020412 MainaI RuleJA WiansFH PoirierM GrantL LeeWM α-glutathione S-transferase: a new biomarker for liver injury? J Appl Lab Med 2016 1 119 28 10.1373/jalm.2016.020412 Open DOISearch in Google Scholar

6. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol 2015;63:503–14. doi: 10.1016/j.jhep.2015.04.016 ChenM SuzukiA BorlakJ AndradeRJ LucenaMI Drug-induced liver injury: Interactions between drug properties and host factors J Hepatol 2015 63 503 14 10.1016/j.jhep.2015.04.016 Open DOISearch in Google Scholar

7. Zhou Y, Wang J, Zhang D, Liu J, Wu Q, Chen J, Tan P, Xing B, Han Y, Zhang P, Xiao X, Pei J. Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs. Chin Med 2021;16(1):135. doi: 10.1186/s13020-021-00543-x ZhouY WangJ ZhangD LiuJ WuQ ChenJ TanP XingB HanY ZhangP XiaoX PeiJ Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs Chin Med 2021 16 1 135 10.1186/s13020-021-00543-x Open DOISearch in Google Scholar

8. Prysyazhnyuk V, Sydorchuk L, Sydorchuk R, Prysiazhniuk I, Bobkovych K, Buzdugan I, Dzuryak V, Prysyazhnyuk P. Glutathione-S-transferases genes-promising predictors of hepatic dysfunction. World J Hepatol 2021;13:620–33. doi: 10.4254/wjh.v13.i6.620 PrysyazhnyukV SydorchukL SydorchukR PrysiazhniukI BobkovychK BuzduganI DzuryakV PrysyazhnyukP Glutathione-S-transferases genes-promising predictors of hepatic dysfunction World J Hepatol 2021 13 620 33 10.4254/wjh.v13.i6.620 Open DOISearch in Google Scholar

9. Chanhom N, Wattanapokayakit S, Satproedprai N, Suvichapanich S, Mahasirimongkol S, Chaikledkaew U, Udomsinprasert W, Mushiroda T, Jittikoon J. CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients. Heliyon 2021;7:e06852. doi: 10.1016/j.heliyon.2021.e06852 ChanhomN WattanapokayakitS SatproedpraiN SuvichapanichS MahasirimongkolS ChaikledkaewU UdomsinprasertW MushirodaT JittikoonJ CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients Heliyon 2021 7 e06852 10.1016/j.heliyon.2021.e06852 Open DOISearch in Google Scholar

10. Lucena MI, Andrade RJ, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, Fernández MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agúndez JAG. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588–96. doi: 10.1002/hep.22370 LucenaMI AndradeRJ MartínezC UlzurrunE García-MartínE BorrazY FernándezMC Romero-GomezM CastiellaA PlanasR CostaJ AnzolaS AgúndezJAG Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury Hepatology 2008 48 588 96 10.1002/hep.22370 Open DOISearch in Google Scholar

11. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011;14:1069–74. doi: 10.1017/S1461145711000617 GawrylukJW WangJF AndreazzaAC ShaoL YathamLN YoungLT Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia Int J Neuropsychopharmacol 2011 14 1069 74 10.1017/S1461145711000617 Open DOISearch in Google Scholar

12. Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T. Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 2020;10:1667. doi: 10.3389/fphar.2019.01667 FuS WuD JiangW LiJ LongJ JiaC ZhouT Molecular biomarkers in drug-induced liver injury: challenges and future perspectives Front Pharmacol 2020 10 1667 10.3389/fphar.2019.01667 Open DOISearch in Google Scholar

13. Karahalil B, Engin AB, Coşkun E. Could 8-oxoguanine DNA glycosylase 1 Ser326Cys polymorphism be a biomarker of susceptibility in cancer? Toxicol Ind Health 2014;30:814–25. doi: 10.1177/0748233712463777 KarahalilB EnginAB CoşkunE Could 8-oxoguanine DNA glycosylase 1 Ser326Cys polymorphism be a biomarker of susceptibility in cancer? Toxicol Ind Health 2014 30 814 25 10.1177/0748233712463777 Open DOISearch in Google Scholar

14. Pinheiro DS, Santos RDS, de Brito RB, Cruz AHDs, Ghedini PC, Reis AAS. GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients. PLoS One 2017;12(8):e0183812. doi: 10.1371/journal.pone.0183812 PinheiroDS SantosRDS de BritoRB CruzAHDs GhediniPC ReisAAS GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients PLoS One 2017 12 8 e0183812 10.1371/journal.pone.0183812 Open DOISearch in Google Scholar

15. Kim SK, Kang SW, Chung JH, Park HJ, Cho KB, Park MS. Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1) and schizophrenia risk: A meta-analysis. Int J Mol Sci 2015;16:19602–11. doi: 10.3390/ijms160819602 KimSK KangSW ChungJH ParkHJ ChoKB ParkMS Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1) and schizophrenia risk: A meta-analysis Int J Mol Sci 2015 16 19602 11 10.3390/ijms160819602 Open DOISearch in Google Scholar

16. Yan C, Duan L, Fu C, Tian C, Zhang B, Shao X, Zhu G. Association between glutathione S-sransferase (GST) polymorphisms and schizophrenia in a Chinese Han population. Neuropsych Dis Treat 2020;16:479–87. doi: 10.2147/NDT.S235043 YanC DuanL FuC TianC ZhangB ShaoX ZhuG Association between glutathione S-sransferase (GST) polymorphisms and schizophrenia in a Chinese Han population Neuropsych Dis Treat 2020 16 479 87 10.2147/NDT.S235043 Open DOISearch in Google Scholar

17. Sakata S, Shinkai T. A functional polymorphism (Ser326Cys) of the human 8-oxoguanine DNA glycosylase (hOGG1) gene and schizophrenia. Psychiat Res 2010;177:268–9. doi: 10.1016/j.psychres.2010.02.007 SakataS ShinkaiT A functional polymorphism (Ser326Cys) of the human 8-oxoguanine DNA glycosylase (hOGG1) gene and schizophrenia Psychiat Res 2010 177 268 9 10.1016/j.psychres.2010.02.007 Open DOISearch in Google Scholar

18. American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders. 4^th ed. Washington (DC): American Psychiatric Publishing, Inc.; 1994 [displayed 15 February 2024]. Available at https://img3.reoveme.com/m/2ab8dabd068b16a5.pdf American Psychiatric Association Diagnostic and Statistical Manual of mental Disorders 4th ed Washington (DC) American Psychiatric Publishing, Inc. 1994 [displayed 15 February 2024]. Available at https://img3.reoveme.com/m/2ab8dabd068b16a5.pdf Search in Google Scholar

19. Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D. Tolérance hépatique des antipsychotiques atypiques [Hepatic tolerance of atypical antipsychotic drugs, in French]. Encephale 2002;28(6 Pt 1):542–51. PMID: 12506267 DumortierG CabaretW StamatiadisL SabaG BenadhiraR RocamoraJF Aubriot-DelmasB GlikmanJ JanuelD Tolérance hépatique des antipsychotiques atypiques [Hepatic tolerance of atypical antipsychotic drugs, in French] Encephale 2002 28 6 Pt 1 542 51 12506267 Search in Google Scholar

20. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255–60. doi: 10.1016/j.pnpbp.2007.05.005 AtasoyN ErdoganA YalugI OzturkU KonukN AtikL UstundagY A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study Prog Neuropsychopharmacol Biol Psychiatry 2007 31 1255 60 10.1016/j.pnpbp.2007.05.005 Open DOISearch in Google Scholar

21. Karahalil B, Kocabaş NA. hOGG1 SER326CYS genetic polymorphism in a Turkish population. Arch Toxicol 2005;79:377–80. doi: 10.1007/s00204-005-0665-5 KarahalilB KocabaşNA hOGG1 SER326CYS genetic polymorphism in a Turkish population Arch Toxicol 2005 79 377 80 10.1007/s00204-005-0665-5 Open DOISearch in Google Scholar

22. Gönül N, Kadioglu E, Kocabaş NA, Ozkaya M, Karakaya AE, Karahalil B. The role of GSTM1, GSTT1, GSTP1, and OGG1 polymorphisms in type 2 diabetes mellitus risk: A case-control study in a Turkish population. Gene 2012;505:121–7. doi: 10.1016/j.gene.2012.05.025 GönülN KadiogluE KocabaşNA OzkayaM KarakayaAE KarahalilB The role of GSTM1, GSTT1, GSTP1, andOGG1 polymorphisms in type 2 diabetes mellitus risk: A case-control study in a Turkish population Gene 2012 505 121 7 10.1016/j.gene.2012.05.025 Open DOISearch in Google Scholar

23. Uřinovská R, Brozmanová H, Sištík P, Silhán P, Kacířová I, Lemr K, Grundmann M. Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012;907:101–7. doi: 10.1016/j.jchromb.2012.09.009 UřinovskáR BrozmanováH SištíkP SilhánP KacířováI LemrK GrundmannM Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum J Chromatogr B Analyt Technol Biomed Life Sci 2012 907 101 7 10.1016/j.jchromb.2012.09.009 Open DOISearch in Google Scholar

24. Karahalil B, Elkama A, Ak M, Nemutlu E. Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms. Toxicol Res (Camb) 2022;11:547–56. doi: 10.1093/toxres/tfac034 KarahalilB ElkamaA AkM NemutluE Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms Toxicol Res (Camb) 2022 11 547 56 10.1093/toxres/tfac034 Open DOISearch in Google Scholar

25. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91. doi: 10.3758/BF03193146 FaulF ErdfelderE LangAG BuchnerA G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences Behav Res Methods 2007 39 175 91 10.3758/BF03193146 Open DOISearch in Google Scholar

26. Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K. Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury. Can J Gastroenterol Hepatol 2019;2019:5850787. doi: 10.1155/2019/5850787 CzuczejkoJ Mila-KierzenkowskaC Szewczyk-GolecK Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury Can J Gastroenterol Hepatol 2019 2019 5850787 10.1155/2019/5850787 Open DOISearch in Google Scholar

27. Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases. Can J Psychiatry 2003;48(3):210. doi: 10.1177/070674370304800313 KolpeM RavasiaS Effect of olanzapine on the liver transaminases Can J Psychiatry 2003 48 3 210 10.1177/070674370304800313 Open DOISearch in Google Scholar

28. Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced hepatotoxicity in a young Chinese patient. Hong Kong Med J 2009;15:394–6. PMID: 19801701 LuiSY TsoS LamM CheungEF Possible olanzapine-induced hepatotoxicity in a young Chinese patient Hong Kong Med J 2009 15 394 6 19801701 Search in Google Scholar

29. Ciba M, Ak M, Karahalil B. Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility. Minerva Psichiatrica 2016;57:62–71. CibaM AkM KarahalilB Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility Minerva Psichiatrica 2016 57 62 71 Search in Google Scholar

30. Manceaux P, Constant E, Zdanowicz N, Jacques D, Reynaert C. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature. Psychiatr Danub 2011;23(Suppl 1):S15–7. PMID: 21894094 ManceauxP ConstantE ZdanowiczN JacquesD ReynaertC Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature Psychiatr Danub 2011 23 Suppl 1 S15 7 21894094 Search in Google Scholar

31. Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1163–6. doi: 10.1016/j.pnpbp.2006.03.014 OzcanliT ErdoganA OzdemirS OnenB OzmenM DoksatK SonsuzA Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity Prog Neuropsychopharmacol Biol Psychiatry 2006 30 1163 6 10.1016/j.pnpbp.2006.03.014 Open DOISearch in Google Scholar

32. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547–56. doi: 10.1176/appi.ajp.2007.06111932 TohenM KryzhanovskayaL CarlsonG DelbelloM WozniakJ KowatchR WagnerK FindlingR LinD Robertson-PlouchC XuW DittmannRW BiedermanJ Olanzapine versus placebo in the treatment of adolescents with bipolar mania Am J Psychiatry 2007 164 1547 56 10.1176/appi.ajp.2007.06111932 Open DOISearch in Google Scholar